NDA 220358 · Vanda Pharms INC
Bysanti
Milsaperidone · Oral
NovelCDER novel approval, Feb 20, 2026: To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 20, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
1 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Feb 27, 2026.
BYSANTI ™ is indicated for the: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . BYSANTI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )
Mechanism: The mechanism of action of milsaperidone in the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults is unknown. However, the efficacy of milsaperidone in these conditions could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo. Milsaperidone has an in vitro receptor binding profile similar to iloperidone.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
7 products under this application
- BYSANTI · MILSAPERIDONE 4MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 1MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 10MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 6MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 2MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 12MG · TABLET, ORAL · Prescription
- BYSANTI · MILSAPERIDONE 8MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Milsaperidone" as an intervention, any sponsor and status, largest first.
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT06830044 · 500 participants (planned) · Start Mar 3, 2025 · Primary completion Mar 2028
Drug: Milsaperidone; Placebo · For: Major Depressive Disorder (MDD)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Garden Grove, California · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Vanda Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.